Prévisions

L'objectif de cours moyen des analystes est de +0,86€ (−78,55%). La médiane est de +0,86€ (−78,55%).

Acheter	6
Conserver	1
Vendre	0

Actualités Accéder au fil d'actualités

Beyond Air sells 58% NeuroNOS stake to Univo and receives share package

Beyond Air sells its approximately 58% stake in NeuroNOS to Univo and receives common shares equal to 19.99% of Univo, plus warrants for an additional 19.99% (exercise price $0.01; term five years). Certain IP and development assets of NeuroNOS will be transferred to NeuroNOS. Beyond Air is entitled to development milestones of up to $6.5 million and commercial milestones of up to $26.0 million. The transaction is subject to regulatory, exchange- and consent-related approvals and other customary closing conditions. » Plus sur de.investing.com
Beyond Air meets Nasdaq requirements after 1:20 reverse split

Beyond Air announced that a 1:20 reverse stock split brought its minimum bid price to at least $1.00; the stock recorded 17 trading days with closing prices of at least $1.00 from July 13 to August 4 and therefore remains listed on Nasdaq, but is subject to a one-year monitoring period. The company reported fiscal 2026 revenue rising to $7.7 million and a positive gross profit of $300,000, while net loss narrowed to $33.2 million ($4.01 per share). The stock last traded at $5.56, is down roughly 90% from a year earlier, and has a market capitalization of about $4.08 million; in pre-market trading it fell about 9.85%. » Plus sur de.investing.com
Beyond Air reports significantly smaller annual loss and strong revenue growth

Beyond Air released quarterly figures for the period ending 31 March 2026: EPS was -0.77 USD for the quarter (previous year -1.80 USD) with revenue of 1.9 million USD (+66.09%). For the fiscal year the company reports EPS of -4.01 USD versus -13.80 USD in the prior year, and annual revenue rose to 7.68 million USD (+107.01%). » Plus sur finanzen.net

Données financières de l'entreprise

Au dernier trimestre, Beyond Air a réalisé un chiffre d'affaires de 1,55M€ et un bénéfice net de −6,95M€

(EUR)	juin 2026	YoY
Chiffre d'affaires	+1,55M	3,74%
Bénéfice brut	+197,15k	48,95%
Bénéfice net	−6,95M	6,55%
EBITDA	−5,66M	1,01%

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	+3,04M€
Nombre d'actions	720,53k
Plus haut/bas sur 52 semaines	+82,07€ - +3,76€
Dividendes	Non
Bêta	0,15
Ratio P/E	−0,09
Ratio PEG	0,00
Ratio P/B	+1,77
Ratio P/S	+0,46

Profil de l'entreprise

Beyond Air, Inc. ist ein Medizintechnik- und Biopharmaunternehmen im klinischen Stadium, das Stickstoffmonoxid (NO)-Generatoren und -Verabreichungssysteme entwickelt. Das Unternehmen entwickelt das LungFit-System, ein NO-Generator- und Verabreichungssystem, das sich in der klinischen Erprobung für die Behandlung von persistierendem Lungenhochdruck bei Neugeborenen, akuter viraler Lungenentzündung, einschließlich COVID-19, Bronchiolitis und nichttuberkulösen Mykobakterien-Lungeninfektionen sowie soliden Tumoren befindet. Es ist in Israel, Irland, Australien und der Europäischen Union tätig. Das Unternehmen war früher als AIT Therapeutics, Inc. bekannt und änderte im Juni 2019 seinen Namen in Beyond Air, Inc. Der Sitz von Beyond Air, Inc. befindet sich in Garden City, New York.

Nom	Beyond Air
PDG	Robert Goodman
Siège social	Garden City, ny États-Unis
Site web	beyondair.net
Secteur	Consommation discrétionnaire
Industrie	Biens de consommation durables
Introduction en bourse	12/06/2018
Employés	54